These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30944075)

  • 41. DNA-Templated Silver Nanocluster/Porphyrin/MnO
    Yao Y; Li N; Zhang X; Ong'achwa Machuki J; Yang D; Yu Y; Li J; Tang D; Tian J; Gao F
    ACS Appl Mater Interfaces; 2019 Apr; 11(15):13991-14003. PubMed ID: 30901195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nanomedicine and personalised medicine: understanding the personalisation of health care in the molecular era.
    Noury M; López J
    Sociol Health Illn; 2017 May; 39(4):547-565. PubMed ID: 27782304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantitative determination of
    Clausen AS; Østergaard DE; Holmberg P; Henriksen JR; Tham J; Damborg PP; Jensen AI; Kjaer A; Hansen AE; Andresen TL
    J Control Release; 2020 Nov; 327():737-746. PubMed ID: 32920081
    [No Abstract]   [Full Text] [Related]  

  • 44. Imaging and therapeutic applications of persistent luminescence nanomaterials.
    Liu J; Lécuyer T; Seguin J; Mignet N; Scherman D; Viana B; Richard C
    Adv Drug Deliv Rev; 2019 Jan; 138():193-210. PubMed ID: 30414492
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy.
    Jo SD; Ku SH; Won YY; Kim SH; Kwon IC
    Theranostics; 2016; 6(9):1362-77. PubMed ID: 27375785
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carbon dots: emerging theranostic nanoarchitectures.
    Mishra V; Patil A; Thakur S; Kesharwani P
    Drug Discov Today; 2018 Jun; 23(6):1219-1232. PubMed ID: 29366761
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Voices in Molecular Pharmaceutics: Meet Dr. Weijun Wei Who Is Developing Theranostic Nuclear Medicine Agents for Clinical Use.
    Wei W
    Mol Pharm; 2022 Oct; 19(10):3456. PubMed ID: 35926185
    [No Abstract]   [Full Text] [Related]  

  • 48. Exogenous/Endogenous-Triggered Mesoporous Silica Cancer Nanomedicine.
    Yang B; Chen Y; Shi J
    Adv Healthc Mater; 2018 Oct; 7(20):e1800268. PubMed ID: 29938917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions.
    Lalu L; Tambe V; Pradhan D; Nayak K; Bagchi S; Maheshwari R; Kalia K; Tekade RK
    J Control Release; 2017 Dec; 268():19-39. PubMed ID: 28756272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Engineered Theranostic Magnetic Nanostructures: Role of Composition and Surface Coating on Magnetic Resonance Imaging Contrast and Thermal Activation.
    Nandwana V; Ryoo SR; Kanthala S; De M; Chou SS; Prasad PV; Dravid VP
    ACS Appl Mater Interfaces; 2016 Mar; 8(11):6953-61. PubMed ID: 26936392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The theranostic nanoagent Mo
    Zhang Q; Huang W; Yang C; Wang F; Song C; Gao Y; Qiu Y; Yan M; Yang B; Guo C
    Biomater Sci; 2019 Jun; 7(7):2729-2739. PubMed ID: 31017137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Nanomedicine : Magnetic nanoparticles for drug delivery and hyperthermia - new chances for cancer therapy].
    Alexiou C; Tietze R; Schreiber E; Lyer S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Aug; 53(8):839-45. PubMed ID: 20700784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intraparticle Molecular Orbital Engineering of Semiconducting Polymer Nanoparticles as Amplified Theranostics for in Vivo Photoacoustic Imaging and Photothermal Therapy.
    Lyu Y; Fang Y; Miao Q; Zhen X; Ding D; Pu K
    ACS Nano; 2016 Apr; 10(4):4472-81. PubMed ID: 26959505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine.
    Chen F; Hong H; Goel S; Graves SA; Orbay H; Ehlerding EB; Shi S; Theuer CP; Nickles RJ; Cai W
    ACS Nano; 2015; 9(4):3926-34. PubMed ID: 25843647
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gold nanostructures as cancer theranostic probe: promises and hurdles.
    Navyatha B; Nara S
    Nanomedicine (Lond); 2019 Mar; 14(6):766-796. PubMed ID: 30794100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Composition-property relationships in multifunctional hollow mesoporous carbon nanosystems for PH-responsive magnetic resonance imaging and on-demand drug release.
    Zhang S; Qian X; Zhang L; Peng W; Chen Y
    Nanoscale; 2015 May; 7(17):7632-43. PubMed ID: 25785502
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Newly Emerging Theranostic Agents for Simultaneous Cancertargeted Imaging and Therapy.
    Luo S; Yang X; Shi C
    Curr Med Chem; 2016; 23(5):483-97. PubMed ID: 26695513
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Upconversion nanotheranostics: emerging designs for integration of diagnosis and therapy.
    Muthu MS; Mehata AK; Viswanadh MK
    Nanomedicine (Lond); 2017 Mar; 12(6):577-580. PubMed ID: 28244815
    [No Abstract]   [Full Text] [Related]  

  • 59. Nanotechnology: 21st century revolution in restorative healthcare.
    Venugopal JR; Ramakrishna S
    Nanomedicine (Lond); 2016 Jun; 11(12):1511-3. PubMed ID: 27199155
    [No Abstract]   [Full Text] [Related]  

  • 60. EDITORIAL: Medicinal Chemistry of Nanomaterials for Cancer Theranostics.
    Liang F; Zhang C
    Curr Top Med Chem; 2017; 17(16):1803-1804. PubMed ID: 28589852
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.